Reaction
Generalised Pustular Psoriasis reporting signals
As of the last recalculation, Generalised Pustular Psoriasis appears in 255 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is TERBINAFINE HYDROCHLORIDE (PRR 95.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Terbinafine Hydrochloride | 10 | 95.6 | 95.7 |
| Adalimumab-Fkjp | 35 | 71.3 | 71.4 |
| Adalimumab-Aaty | 35 | 69.8 | 69.9 |
| Adalimumab-Adaz | 35 | 62.6 | 62.6 |
| Cefepime | 8 | 47.0 | 47.0 |
| Bimekizumab | 9 | 35.7 | 35.7 |
| Guselkumab | 11 | 26.2 | 26.2 |
| Ixekizumab | 7 | 15.9 | 15.9 |
| Apremilast | 18 | 10.7 | 10.7 |